ArticleMedical science monitor : international medical journal of experimental and clinical research2019
lncRNA-D16366 Is a Potential Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Combinatorial Gene Expression Profiling of SerumInternational journal of molecular sciences · 2024Pooled it
- LncRNA TAF1A-AS1 regulates the progression in hepatocellular carcinoma by targeting miR-664b-3p/USP22 axis.Discover oncology · 2026Article
- Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.Molecular cancer · 2026Review
- Prognostic Value of VPS45 in HCC and Its Correlation with Immune Microenvironment.Journal of hepatocellular carcinoma · 2026Article
- Long non-coding RNA-based single and combination independent prognostic biomarkers for hepatocellular carcinoma.Discover oncology · 2025Review
- Glycolysis-related lncRNA FTX upregulates YAP1 to facilitate colorectal cancer progression via sponging miR-215-3p.Scientific reports · 2025Article
- Long non-coding RNA PRKG1-AS1 promotes cell proliferation and migration in lung adenocarcinoma.Respiratory research · 2025Article
- Construction of a cuproptosis‑related lncRNA signature to predict biochemical recurrence of prostate cancer.Oncology letters · 2024Article
- Review
- The multifaceted perspectives on the regulation of lncRNAs in hepatocellular carcinoma ferroptosis: from bench-to-bedside.Clinical and experimental medicine · 2024Review
- Diagnosis of the Initial Stage of Hepatocellular Carcinoma: A Review.Current pharmaceutical design · 2024Review
- SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma.Immunogenetics · 2023Article
- Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma.Frontiers in pharmacology · 2023Article
- Long noncoding RNA MyD88 functions as a promising diagnostic biomarker in hepatocellular carcinoma.Frontiers in endocrinology · 2023Article
- PRR34-AS1 promotes exosome secretion of VEGF and TGF-β via recruiting DDX3X to stabilize Rab27a mRNA in hepatocellular carcinoma.Journal of translational medicine · 2022Article
- Article
- LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma.Journal of clinical laboratory analysis · 2022Article
- The activation of MActa biochimica et biophysica Sinica · 2022Article
- Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma.Heliyon · 2022Article
- Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.Cells · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Long non-coding RNAs (lncRTNAs) are a new focus in cancer research. Although lncRNAs have no protein coding capacity, they are important in epigenetics as well as in regulating gene expression, playing an important role in various cancers. In the current study, we investigated the roles of lncRNA-D16366 in hepatocellular carcinoma (HCC) and expected to find a new biomarker for early detection and prognosis of the disease. MATERIAL AND METHODS Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of lncRNA-D16366 in tissue and serum samples. The relationship between lncRNA-D16366 expression and clinicopathologic characteristics of patients with HCC was analyzed to estimate whether it was involved in malignancy development. Then, potential diagnostic and prognostic values were evaluated via receiver operating characteristic (ROC) curve, Kaplan-Meier and Cox regression analysis, respectively. RESULTS lncRNA-D16366 was proved to be decreased in the tissues and serum among patients with HCC compared with the corresponding controls. Its expression was influenced by tumor size, HbsAg, portal vein tumor thrombus, Child-Pugh score, therapies, and neoplasm metastasis. It had high diagnostic value, with an AUC of 0.752, accompanied by a sensitivity of 65.5% and a specificity of 84.6%. In addition, it was related to the prognosis of HCC. CONCLUSIONS lncRNA-D16366 was decreased in HCC, and might be an independent diagnostic and prognostic indicator in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.